Friedberg was talking about long‑run manufacturing costs for cell therapies like CAR‑T, on the order of years to decades after 2022. As of late 2025, commercial autologous CAR‑T cost of goods per patient is still very high: analyses estimate manufacturing COGS around 95,000 USD per dose or 170,000–220,000 USD per batch, and even optimistic process‑optimization models for autologous therapies project future costs in the tens of thousands, not below 5,000 USD. (appliedcells.com) Emerging work on allogeneic or off‑the‑shelf CAR‑T and CAR‑NKT suggests that, in principle, batch manufacturing could reduce the per‑patient therapy cost to roughly 3,990–10,000 USD or about 5,000 USD in some modeled scenarios, but these are projections or pre‑commercial platforms rather than widely implemented real‑world costs today. (cancerci.biomedcentral.com) Since only about three years have passed since the 2022 prediction and the stated time horizon was up to a couple of decades, and because the claim was about what could be achievable in the long run rather than what would happen by a specific near‑term date, there is not yet enough elapsed time or empirical evidence to say definitively whether costs will fall below 5,000 USD per patient. Therefore the prediction is still in progress and must be rated as inconclusive.